Project Grant HT9425261E384
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $560K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $1.036 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective November 1, 2025, through October 31, 2029. The award supports research to identify NEK5 (NIMA-related kinase 5) as a hidden driver gene in kidney cancer development and progression. This four-year research initiative will deliver hypothesis-driven basic and...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $980,501 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on June 15, 2025, with a completion date of June 14, 2028. The grant supports research investigating cell intrinsic and extrinsic modifiers of bone marrow failure (BMF) progression in SAMD9L syndromes. This three-year research initiative aligns with the DHA's...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $1.68M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to investigate pre-mRNA splicing as a therapeutic vulnerability in pediatric liver cancer. The three-year award, obligated on September 30, 2025, with completion targeted for September 29, 2028, supports hypothesis-driven biomedical research designed to identify and develop...
- This Project Grant award for $1,340,665.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to St. Jude Children's Research Hospital Inc. The award supports research focused on the FGFR pathway as a lead therapeutic vulnerability in pediatric ependymoma, a type of brain cancer in children. The project will be conducted over 3 years, from September 1, 2023 to August 31, 2026, and aims to advance the development of effective...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,295,000.00 to St. Jude Children's Research Hospital Inc. to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The award period runs from September 1, 2024 to August 31, 2028. This research project builds upon St. Jude's extensive experience in pediatric cancer and other life-threatening diseases in...
- Federal Grant Award Summary ST Jude Children's Research Hospital Inc. received a $647,502 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2031. This five-year research initiative focuses on developing novel anti-cancer therapeutics by targeting DDX19A, an RNA helicase identified as a genomic dependency in Ewing sarcoma, an aggressive pediatric bone malignancy. The research addresses...
- Federal Grant Award Summary Children's Hospital Los Angeles received a $1.4 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The award funds research to develop CTSR-enhanced chimeric antigen receptor (CAR) T cells designed to overcome the immunosuppressive tumor microenvironment and improve immunotherapy outcomes for pediatric brain tumors. This three-year...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1,014,596 Project Grant award dated July 15, 2026, from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support research on optimizing immunotherapy for pediatric solid tumors. The three-year award, with an ultimate completion date of July 14, 2029, funds research initiatives at the institute's Boston, Massachusetts location aimed at advancing...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $723,699 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded July 15, 2026, with an ultimate completion date of July 14, 2029. The award supports the project "Optimizing Immunotherapy for Pediatric Solid Tumors," conducted at the institute's Boston, Massachusetts location. Based on the institute's recent portfolio and the DHA...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Trustees of Columbia University in the City of New York a $1,099,932 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. The grant funds research titled "Optimization of Targeted Drug Delivery and Radiosensitizing Strategies for Pediatric Diffuse Midline Glioma," to be conducted at Columbia University's Health Sciences Division in New...